Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-01 18:03:52 - browse：7522

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Health tech investors get more selective as pandemic boom fades

WSS

Lasker Awards 2023: Winners in biomedical research

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

CDC advisers recommend seasonal use of Pfizer RSV shot

J&J lung cancer data amount to new salvo against AstraZeneca

Smaller biotechs seek to piggyback on weight loss drug boom

STAT Summit: Ending the crisis of Black deaths in the U.S.

hotspot

Wikipedia

focus

Peter Hotez and the public health issue of online harassment

Cassava Sciences’ Alzheimer’s clinical trials should be halted

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Summit: The economic case for universal basic health care

Activists slam private health insurers over coverage restrictions

Study on Amgen’s bispecific immunotherapy produces positive data

Novavax promises a turnaround & Lilly roils the obesity market

Lasker Awards 2023: Winners in biomedical research

United colonoscopy coverage change 'may cost lives,' doctors say

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Wikipedia

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Merck, Daiichi strike cancer drug pact worth up to $22 billion

J&J lung cancer data amount to new salvo against AstraZeneca

How AI can help patients find reliable information about doctors

Health tech investors get more selective as pandemic boom fades

STAT Summit: Ending the crisis of Black deaths in the U.S.

hotspot

leisure time

entertainment

leisure time